ERBB2 and breast cancer: Despite the implementation of these selective therapies against luminal and HER2 positive breast cancers, approximately 20–30% of the patients that are treated with endocrine therapy and 70% of patients that are treated with Trastuzumab develop resistance, and progress to a more advanced disease [11].